Schroder Investment Management Group Sells 1,089 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Schroder Investment Management Group cut its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 1.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,490 shares of the company’s stock after selling 1,089 shares during the quarter. Schroder Investment Management Group owned approximately 0.31% of Disc Medicine worth $5,636,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP grew its holdings in shares of Disc Medicine by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after purchasing an additional 83,731 shares during the last quarter. Vanguard Group Inc. boosted its position in Disc Medicine by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company’s stock valued at $67,727,000 after buying an additional 18,716 shares in the last quarter. State Street Corp grew its stake in shares of Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after buying an additional 235,115 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Disc Medicine by 68.2% during the third quarter. Janus Henderson Group PLC now owns 749,827 shares of the company’s stock worth $36,828,000 after buying an additional 303,954 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Disc Medicine by 17.6% in the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock valued at $23,333,000 after acquiring an additional 70,983 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $41.22 on Friday. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -10.36 and a beta of 0.73. The stock’s 50-day moving average is $53.45 and its 200 day moving average is $56.04. Disc Medicine, Inc. has a one year low of $25.64 and a one year high of $68.73.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Activity

In related news, CEO John D. Quisel sold 5,574 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $304,228.92. Following the completion of the sale, the chief executive officer now directly owns 154,828 shares of the company’s stock, valued at $8,450,512.24. The trade was a 3.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the completion of the transaction, the chief operating officer now owns 40,555 shares in the company, valued at approximately $2,213,491.90. The trade was a 3.82 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 361,690 shares of company stock worth $19,648,094. Company insiders own 4.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a report on Friday, March 7th. TD Cowen initiated coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a “buy” rating for the company. Scotiabank boosted their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, March 3rd. Cantor Fitzgerald raised their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Finally, Wedbush reissued an “outperform” rating and issued a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $93.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.